Both in Diagnostics
Immucell vs Intellia Therapeutics
Over the past year ICCC returned +65.1% and NTLA returned −9.3%; their daily moves had a correlation of 0.06.
ICCC +65.1% NTLA −9.3%Growth of $1, one year, split-adjusted
| Metric | ICCC | NTLA |
|---|---|---|
| Price | $10.25 | $11.86 |
| Market cap | $93.1M | $1.66B |
| Today | −2.94% | +1.72% |
| 1 month | +5.1% | −7.0% |
| 6 months | +15.3% | −10.9% |
| Year to date | +66.7% | +31.9% |
| 1 year | +64.3% | −6.0% |
| Revenue growth (YoY) | +11.5% | −46.2% |
| Gross margin | 33.9% | 100.0% |
| Net margin | 25.5% | −1392.3% |
| P/E (TTM) | 118.2× | — |
| Price / sales | 3.0× | 27.9× |
| Net cash | $557.3K | $437.8M |
| Dividend yield | — | — |
| Volatility (60d) | 38.3% | 62.6% |
| Short % of float | 0.3% | 38.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).